RT Journal Article
SR Electronic
T1 Genetic admixture predictors of fetal alcohol spectrum disorders (FASD) in the South African Cape Coloured population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.31.24305130
DO 10.1101/2024.03.31.24305130
A1 Carter, R. Colin
A1 Yang, Zikun
A1 Akkaya-Hocagil, Tugba
A1 Jacobson, Sandra W.
A1 Jacobson, Joseph L.
A1 Dodge, Neil C.
A1 Hoyme, H. Eugene
A1 Zeisel, Steven H.
A1 Meintjes, Ernesta M.
A1 Kizil, Caghan
A1 Tosto, Giuseppe
YR 2024
UL http://medrxiv.org/content/early/2024/04/01/2024.03.31.24305130.1.abstract
AB Ancestrally admixed populations are underrepresented in genetic studies of complex diseases, which are still dominated by European-descent populations. This is relevant not only from a representation standpoint but also because of admixed populations’ unique features, including being enriched for rare variants, for which effect sizes are disproportionately larger than common polymorphisms. Furthermore, results from these populations may be generalizable to other populations. The South African Cape Coloured (SACC) population is genetically admixed, with one of the highest prevalences of fetal alcohol spectrum disorders (FASD) worldwide. We profiled its admixture and examined associations between ancestry profiles and FASD outcomes using two longitudinal birth cohorts (N=308 mothers, 280 children) designed to examine effects of prenatal alcohol exposure on development. Participants were genotyped via MEGA-ex array to capture common and rare variants. Rare variants were overrepresented in our SACC cohorts, with numerous polymorphisms being monomorphic in other reference populations (e.g., ∼30,000 and ∼221,000 variants in gnomAD European and Asian populations, respectively). The cohorts showed global African (51%; Bantu and San); European (26%; Northern/Western); South Asian (18%); and East Asian (5%; largely Southern regions) ancestries. The cohorts exhibited high rates of homozygosity (6%), with regions of homozygosity harboring more deleterious variants when lying within African local-ancestry genomic segments. Both maternal and child ancestry profiles were associated with FASD risk and altered severity of prenatal alcohol exposure-related cognitive deficits in the child. Our findings indicate that the SACC population may be a valuable asset to identify novel disease-associated genetic loci for FASD and other diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by NIH/NIAAA (R01AA016781, R01AA027916, R01AA023503, K23AA020516, U01AA014790), NIH/NIA (U01AG081817, RF1AG082009, U19AG074865), and the Lycaki-Young Fund (State of Michigan). The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Boards/Ethics Committees of Wayne State University (026708B3F, approved August 2011 and annually thereafter), University of Cape Town Faculty of Health Sciences, and Columbia University Irving Medical Center.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes